India Tightens Watch on GLP-1 Drugs Amid Safety and Misuse Concerns
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
#regulation
6 stories
Hims & Hers Stock Retreats as Peptide Market Optimism Fades on Regulatory Uncertainty
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.
India's CDSCO Tightens Oversight on GLP-1 Drugs, Warns Against Weight Loss Misuse
India's Central Drugs Standard Control Organization issued advisories against unsupervised use of semaglutide and tirzepatide for weight loss, cracking down on misleading social media promotions and unapproved compounded versions.
FDA Poised to Reverse 2023 Peptide Ban Following RFK Jr. Advocacy
Federal regulators are moving toward restoring legal access to injectable peptides barred from pharmacy compounding in 2023, which could redirect patients from unregulated online sellers to regulated pharmacy channels.
FDA May Relax Dietary Supplement Warning Label Rules
The FDA is evaluating potential changes to dietary supplement warning label requirements, with pharmacists urged to remain vigilant as regulations may loosen under the current administration.
Australian Financial Review: Inside the Risky, Unregulated World of Peptides
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.